ARTICLE
HPE Miami 2023 | Financing Healthcare Companies in a Challenging Market
March 8-9, 2023
Read time: 3 min
During this session, Sam Koplik, Partner and Stephanie McCann, Partner and Co-Chair of Finance moderated a panel that provided key insights on financing strategies in the current market and discussed specific challenges and opportunities for healthcare financings.
Session panelists included:
- Javier Casillas, Global Chief Credit Officer & Managing Director, WhiteHorse Capital
- Matthew Evans, Managing Director, Head of Healthcare Finance, Monroe Capital
- Scott Gallin, Partner, Linden Capital Partners
- Scott Porter, Managing Director, Brightwood Capital Advisors
Key takeaways included:
- In today’s economy, factors such as inflation, higher interest rates and geopolitical instability are no longer viewed as temporary hurdles. Consequently, lenders view creativity and opportunistic thinking as key to financing deals in this market. That said, the healthcare industry specifically is one of the best positioned to continue growing; lenders are not only seeing resilient demands for healthcare deals but would rather be supporting healthcare over a lot of other industries in the current economy.
- Over the past year, lender-friendly terms have become more prevalent in loan documentation. These terms include higher pricing and fees, reduced deal sizes, the absence of delayed draw term loan (DDTL) facilities, the inclusion of fixed-charge coverage ratio (FCCR) covenants and greater equity contributions from sponsors. While the prevalence of each term varies across the market and among specific lenders, most anticipate that higher pricing will be the first to soften once the market improves. Though lenders can be flexible on pricing, they have little wiggle room to soften other terms, particularly FCCR requirements. Nonetheless, the panelists emphasized that they are evaluating deals on a case-by-case basis as their role is to assess each situation on its merits and not just to follow the market blindly.
- To achieve better financing outcomes, it is essential to view lenders as business partners rather than faceless commodities. Current market conditions have prompted borrowers to seek closer relationships with their lenders, which has led to greater transparency with management teams and sponsors. This is a trend that lenders believe should continue. Accordingly, lenders are actively working to enhance existing relationships, focusing on meeting the needs of their established clients.
- Lenders are showing a strong interest in investing in smaller deals and have ample capital available to do so. This trend, coupled with a shift in valuation trends that allows buyers to pay less for smaller businesses, presents an excellent opportunity for sponsors. Lenders suggest that sponsors maintain open communication with them and also believe that most issues can be resolved through a combination of capital, time and level-headedness. According to the panelists, as long as there is a good deal to be made, the capital will follow suit.

HPE Miami 2023 | Digital Health Investing: Hot Areas for Innovative Healthcare Delivery
ARTICLE
HPE Miami 2023 | Digital Health Investing: Hot Areas for Innovative Healthcare Delivery
March 8-9, 2023
Read time: 3 min
During this session, Partners Stephen Bernstein and Marshall Jackson, Jr. moderated a panel that examined the latest developments in digital health and the factors driving value in the industry.
Session panelists included:
- Alena Antigua, Managing Director, Healthcare Technology, Stifel Financial
- Dr. Ryan Harris, General Partner, Norwest Venture Partners
- Oliver Kharraz, MD, CEO & Founder, Zocdoc
Key takeaways included:
- While the market has had no shortage of digital health companies with massive valuations and excitement to participate in “digital health investing,” investors are now digging deeper to pinpoint the concrete, measurable return on investment that is delivered to patients and providers. There has also been a shift in focus from revenue growth to the macroeconomic factors behind healthcare like customer concentration, models that are scalable over time where sales cycles can be truncated, and identification of technology that fosters interoperability (specifically, what value can be added to the technology over time to solve more than one issue at a single point in time).
- Digital health can be generally organized into three categories: tools that improve administrative efficiency, tools that are diagnostic in nature and deployed digitally and tools that support physician decision-making. Several factors created opportunities for increased efficiency to deliver patient outcomes and increased efficiency in the financing and staffing of healthcare systems, which created momentum for digital health solutions. Those factors include (1) acceleration of the technology adoption curve, (2) increases in valuations, (3) new companies expanding into remote telemedicine, (4) remote patient monitoring and (5) hospitals understanding what technologies they need, creating opportunities to sell tools that will help them regain their competitiveness.
- The panelists elaborated on some of the challenges with navigating the smörgåsbord of regulatory regimes that affect digital health companies. Investors spend a significant amount of time identifying areas of regulatory risk. As operations evolve, compliance with the different regulations on a state-by-state level has created friction and operational complexities. Ultimately, opportunity stems from understanding the patient flow and needs of the business, along with the legal compliance risks, and designing a company to fit in the sweet spot between the two.

HPE Miami 2023 | Hot PPM Specialties: Spotlight on Cardiology, Ortho/PT and GI
ARTICLE
HPE Miami 2023 | Hot PPM Specialties: Spotlight on Cardiology, Ortho/PT and GI
March 8-9, 2023
Read time: 4 min
McDermott Partners Amanda Jester and Joel Rush moderated a panel discussion that examined the market trends shaping physician practice management platforms in cardiology, orthopedics and gastroenterology. The speakers also shared some of the opportunities and challenges they are currently facing in their respective sectors.
Session panelists included:
- Stephen Burhenn, Principal, Ares Management
- Joseph Garcia, CEO, Gastro Health
- Harrison Hunter, Managing Director, Stone Point Capital
Key takeaways included:
- Cardiology, orthopedics and gastroenterology are all highly fragmented markets, but they each feature unique characteristics that should drive investment strategies.
- Cardiology is an attractive investment area because it presents an opportunity to move care out of the hospital and into the outpatient setting.
- Orthopedics as a specialty has experienced organic growth from an aging population and increasing obesity statistics. Plus, more procedures are moving to outpatient facilities and orthopedics often incorporates a high level of ancillary services (e.g., physical therapy and imaging) to provide optimal care for patients. However, this space is experiencing economic pressure from reimbursement rates and inflation, particularly on the ancillary side. Key players in the orthopedic space anticipate that these pressures will drive consolidation to larger platforms.
- Gastroenterology is an attractive specialty because income is relatively balanced between practices, ambulatory surgery centers (ASCs) and ancillary services. Consolidation in this sector is more mature, which has resulted in commercially minded physicians who are comfortable working outside of hospital systems.
- In gastroenterology, a major tool for successful alignment focus is driving income repair for physicians, which requires discipline in diligence and operations. From a diligence standpoint, it is important to develop conservative, supportable projections that can be provided to the doctors. Operationally, investors can add value by providing the opportunity to centralize ancillaries, such as infusion and pathology. Opportunities for income repair often arise in the context of better throughput and via processes that allow everyone to operate at the top of their license and increase physicians’ relative value units.
- Alignment in cardiology is driven by selecting the right partners. This specialty is still underrepresented by private equity platforms but has opportunities for growth in ASCs, imaging and practice management—as long as investors are willing to make the upfront investment in infrastructure.
- ASC development is a significant opportunity area in orthopedics, as many physicians already have ancillary services in their practices. Investors are focused on adding value to their current states before expanding to new states.
- Recruiting and retaining talent remain top of mind across specialties. Gastroenterology has seen early retirements and a corresponding focus on recruiting younger doctors. Since early career doctors are primarily out of fellowships and burdened with debt, the opportunity to earn equity in a practice with peers who are well-respected in the industry can be attractive.
- Private equity is relatively new in cardiology and may be viewed with skepticism. This makes it even more crucial to select the proper partner for a platform practice that is highly regarded in the market. In orthopedics, physicians are focused on understanding the growth that can come from a transaction and knowing that the “second bite at the apple” is worth it.
- Cardiology is ripe with opportunity for value-based care, given the senior focus and capitated risk, especially since the prevailing care delivery is hospital-based. Cardiology has increasingly seen payors eager to engage with a value-based care model. A value-based care model fits well in orthopedics, but there hasn’t been enough interest from physicians to develop momentum yet. Large insurers seem to be extremely focused on high-cost providers, although investors acknowledge that orthopedics may be a follower rather than a leader in the value-based care model. Finally, gastroenterology is already delivered at a lower cost since much of the work is preventative and generally outpatient. Inflammatory bowel disease patients are an area of opportunity to deliver value-based care because they often face complexity and failure to control their condition can result in emergency room visits. Several payors have named gastroenterology as one of their top three specialties of interest for value-based care.

HPE Miami 2023 | Tailwinds Impacting the Surge in Pharma Services Investing
ARTICLE
HPE Miami 2023 | Tailwinds Impacting the Surge in Pharma Services Investing
March 8-9, 2023
Read time: 3 min
During this session, Partners Hunter Sharp and Eleanor West moderated a panel that discussed the future of pharma services and the investment opportunities in this growing industry.
Session panelists included:
- Nick Bell, Director, Robert W. Baird & Co.
- Adam Dolder, Co-Founder & Managing Director, 3 Boomerang Capital
- Geoffrey Tresley, Principal, GTCR
Key takeaways included:
- The current state of the market is characterized by market volatility and a lack of access to liquidity, which has put pressure on client bases and (derivatively) on portfolio companies.
- The focus for investment in 2023 will likely fall toward innovation. In the commercialization space, we are seeing a shift toward digital. Buyers are more sophisticated when it comes to commercialization and will look to more cutting-edge tech while being more discerning in the investments they make.
- With a tough credit market and high bid asks from founders, parties will need to find creative ways to bridge the valuation gap between buyers and sellers.
- With a macro uncertainty around pharma, the market would expect multiples to decrease, although we are not seeing this at a large scale yet.
- COVID-19 provoked lasting changes in the pharma services space, including a broadened interest from an investment perspective, new investors (both strategic and financial) with fresh views and subsector dependence with niche markets overperforming. Nevertheless, there remains uncertainty as to the lasting effect of these changes and whether all of these new players will stay (and continue to find success) in the space long term.

HPE Miami 2023 | Driving Behavioral Health to New Heights
ARTICLE
HPE Miami 2023 | Driving Behavioral Health to New Heights
March 8-9, 2023
Read time: 5 min
During this session, Partner Michael Hacker moderated a panel that explored the opportunities and challenges for investors in behavioral health businesses. They also took a closer look at the current behavioral health system landscape.
Session panelists included:
- Jasmine Chen, Principal, Iron Path Capital
- Dan Davidson, President, Galen Mental Health
- L.A. Galyon IV, Managing Partner, Brentwood Capital Advisors
- Michael Hacker, Partner, McDermott Will & Emery (Moderator)
Key takeaways included:
- The increase in demand for behavioral health services and the decrease in the workforce has pushed both investors and providers to focus on new models to deliver treatment.
- About 20% of Americans have some type of mental health condition. Suicide and overdoses were the highest they had ever been in 2022. While supply is trending upwards, there is a decline in the workforce. Sixty percent of US psychiatrists are over the age of 55 and 60% of US counties don’t even have psychiatrists. There is also a shortage of staff, partly due to low wages and inflation. Social workers and board-certified behavior analysts are incredibly important in the industry, but their wages cannot keep up with the rising cost of living. There is an opportunity here to focus on good training resources and find ways to pay personnel a fair wage to attract a quality and numerous workforce.
- The behavioral health system today is set up to treat acute psychiatric patients while they are receiving care at a facility but not after they are released. This is in stark contrast to other fields of medicine where a patient receives acute care during their stay at a hospital and stepped-down levels of care after they leave. Psychiatry does not have an equivalent model with stepped-down care once a patient is released, which makes it difficult for these patients to see lasting or meaningful improvements. Companies are attempting to flip the paradigm from treating people who are acutely ill to preventing them from reaching that point in the first place. If companies and providers can find ways to unite different sectors and promote synergy, there can be a large positive shift in the system.
- Not only has telehealth changed the way behavioral care is delivered, but it also helped take away the stigma associated with mental health issues. However, telehealth does not completely replace the in-person provider, and thus providers must focus on how to best integrate both virtual and in-person care delivery systems.
- Both venture capital investment and the provision of virtual healthcare have been a huge part of removing the stigma surrounding mental health. The virtual delivery of behavioral healthcare has greatly expanded its outreach to include a wider audience. Today, obtaining behavioral services from the comfort of one’s home has become more accessible to the general public. Portfolio companies are also interested in pushing into the digital delivery of healthcare. In terms of investment, if a company has invested in technology and data research, this can be seen as an attractive addition that makes the company desirable when selling.
- Investors have not seen many digital-only platforms entering the market. Many virtual companies are now trying to extend to in-person services or are trying to partner with larger in-person providers.
- There are several challenges in the traditional third-party payor model in the mental and behavioral health sector, but private equity investments and virtual healthcare are working to address these challenges.
- The traditional third-party payer model often limits coverage for mental and behavioral health services, which can make it difficult for patients to access the care they need. Even when mental and behavioral health services are covered, patients may still face high out-of-pocket costs. Mental and behavioral health providers are often reimbursed at lower rates than providers in other specialties, which can discourage providers from offering these services. For example, reimbursement rates for in-network psychotherapy are around $20 to $30 but the actual cost of a psychiatrist can start at upwards of $100.
- Private equity firms can address these challenges in different ways, starting with investing in technology. Firms can invest in technology solutions that streamline administrative tasks, such as preauthorization and claims processing. These solutions can reduce the administrative burden on providers and allow them to spend more time providing care. Additionally, private equity firms can acquire existing mental and behavioral health providers and invest in their expansion to improve access to care for patients. This can also help to address the shortage of mental and behavioral health providers in certain areas.

EU-US Transatlantic Data Flows Framework: EU Supervisors Shine Light at the End of the Tunnel
ARTICLE / CLIENT ALERT
EU-US Transatlantic Data Flows Framework: EU Supervisors Shine Light at the End of the Tunnel
March 9, 2023
Read time: 7 min
In a recent non-binding opinion, EU regulators expressed timid positivity about the European Commission’s draft adequacy decision on the EU-US transatlantic data flows framework (Data Privacy Framework or DPF). While some fine-tuning clarifications and changes to the draft US adequacy decision are still to be expected, the path to the final adoption of the decision this year seems to finally be in sight. At the same time, EU regulators continue to raise certain long-standing concerns about US authorities’ ability to access transferred personal data as well as the redress mechanism, thereby raising the question of whether the third time will be a charm for the DPF or whether it will succumb to another Schrems III.
WHERE ARE WE NOW ON THE EU-US ADEQUACY DECISION?
Following two previous invalidations of the EU-US adequacy decision by the Court of Justice of the European Union (Schrems I and Schrems II cases), the European Commission and the Biden administration have been involved in lengthy negotiations to re-establish a transatlantic framework for data flows. These negotiations led to US President Joe Biden and European Commission President Ursula von Der Leyen announcing an agreement in principle on the new transatlantic data flow framework in March 2022.
The agreement was implemented with President Biden signing Executive Order 14086 (EO 14086) in October 2022, providing for safeguards on imported EU personal data, particularly by curtailing the access of intelligence agencies and establishing a redress mechanism. Additionally, the United States and the European Union appear to have also agreed on slight revisions to the previous privacy framework that applies to self-certified organizations importing personal data from the European Union.
The European Commission then responded in December 2022 by adopting its draft US adequacy decision, which concluded that the United States now ensures an adequate level of protection for personal data transferred from the European Union.
Recently, the European Data Protection Board (EDPB) added its voice to the chorus of commenters on the new DPF, expressing some reservations but overall applauding the efforts made to date.
WHAT DOES THE EDPB OPINION SAY?
The EDPB Opinion was adopted on February 28, 2023, and focuses on two distinct aspects of the DPF:
- Changes to the US framework made by EO 14086 compared to the previous legal framework
- The DPF Principles, to which certifying organizations must comply and that remain more or less unchanged from the Privacy Shield.
With Regard to the Changes Made by EO 14086
The EDPB recognized the substantial improvements made to the limits and scope of EO 14086 as compared to the previous legal framework, especially in connection with US authorities’ ability to access transferred personal data under US law and the development of a redress mechanism. Nonetheless, the EDPB Opinion expressed concern, including:
- Request to condition the adoption or entry into force: The EDPB Opinion requests that the European Commission conditions its adoption and entry into force of the adequacy decision upon the adoption by the United States of updated policies and procedures to implement EO 14086 by all US intelligence agencies.
- Request to clarify: While the EDPB Opinion requests several clarifications to the DPF, it does not explicitly demand certain changes prior to the adoption of the adequacy decision. For example, the EDPB Opinion notes that under EO 14086, the possibility to collect data in bulk is still permitted under US law. The EDPB Opinion asks the European Commission for clarification in relation to such bulk collection and data retention.
- Request to monitor: Once the US adequacy decision is adopted, the EDPB requested that the European Commission monitor the implementation of the changes to EO 14086, specifically with respect to the practical application of the newly introduced principles of necessity and proportionality as well as the effectiveness of the remedies available to individuals.
With Regard to the DPF Principles
- The EDPB Opinion also identified what the EDPB sees as issues relating to existing DPF Principles. As with the changes to EO 14086 discussed above, the EDPB requested that the European Commission clarify certain principles, but, significantly, the EDPB does not call for the European Commission to halt the adoption of the US adequacy decision. Applicability to processors: The EDPB requests that the DPF clarify which of the DPF Principles are applicable to “processors” or “agents” and which to “controllers.”
- Data subject rights: The EDPB Opinion opposes the publicly available information exception to the right of access, finding it too broad. With respect to the right to object, the EDPB Opinion seeks greater clarity on how individuals can exercise that right.
- Onward transfers: The EDPB Opinion invites the European Commission to clarify that intragroup transfers should not be carved out of the DPF requirements and that transfer impact assessments should be carried out in case of onward transfers to third countries.
- Automated decision-making: The EDPB believes that specific rules concerning automated decision-making are needed to provide sufficient safeguards, including the right for the individual to know the logic involved, to challenge the decision and to obtain human intervention when the decision significantly affects him or her.
- Enforcement mechanisms: In the EDPB’s view, oversight by the Federal Trade Commission must be effective and must be monitored through periodic reviews, including by the EDPB.
WHERE DO WE GO FROM HERE?
The next step is for the European Commission to respond to the EDPB’s requests for clarifications and concerns. The EDPB Opinion is not binding thus the European Commission could either consider adjustments to the draft adequacy decision or take the position that no changes are necessary. The European Commission could also provide written clarifications to the EDPB. Of course, if the European Commission were to agree with some or all of the EDPB’s concerns, the European Commission could try to use the EDPB Opinion as leverage to put pressure on the United States to make more changes to the DPF. If this happens, the adoption of any DPF would necessarily be pushed back.
From the viewpoint of the United States, timing is important in this process. The United States heads into a presidential election cycle later this fall, a time during which politicians like to identify “wins,” of which an adequacy decision would most certainly be one. As a result, US representatives are likely working closely with their European counterparts to try to limit any potential changes to the hard-won DPF terms. At the same time, because of the desire in the United States to have the adequacy decision finalized, the European Commission may also find the United States willing to make minor tweaks to the DPF to address any remaining concerns of the European Commission or the EDPB. Substantive changes to the DPF by the United States, however, seem unlikely.
If the European Commission does not seek any changes to the DPF, as a procedural matter, the next step would be for the European Commission’s draft US adequacy decision to be adopted by a committee of representatives of the 27 EU Member States. The European Parliament could also exercise its right of scrutiny over the adequacy decision. Only after the 27 EU Member States approve the draft adequacy decision can the European Commission adopt its final US adequacy decision. If all goes well, that could be later this year. The future will tell whether the DPF will be a long-term solution to transatlantic data flows woes.

HPE Miami 2023 | 2023: WTF? | What’s the (Winning) Formula?
ARTICLE
HPE Miami 2023 | 2023: WTF? | What’s the (Winning) Formula?
March 8-9, 2023
Read time: 3 min
During this session, Chairman Ira Coleman moderated a panel that discussed the economic and market challenges the healthcare private equity (PE) industry will face in 2023 and beyond.
Session panelists included:
- Alex Albert, Founding Partner, Patient Square Capital
- Amy Christensen, Partner & Co-Head of Healthcare, The Vistria Group
- Michael Dal Bello, Partner, Curewell Capital
- Paige Daly, Partner, Harvest Partners
- Jeremy Gelber, Senior Managing Director, Centerbridge Partners
Key takeaways included:
- Healthcare PE firms’ investment policies should still be centered around improving patient quality of care and well-being. PE firms and management teams will need to stay ahead of the curve and can do so by investing in technology that will help further these goals. Additionally, PE firms should be creative in their investment strategies and proactive when identifying and approaching investment opportunities as capital providers.
- Exit strategies for healthcare PE firms are shifting because of changes in the economy. Now, PE firms should focus on investing in solid businesses that have defined goals and strong business practices. To that end, it is crucial that PE firms have a clear idea of what the business profile should look like at the exit and then work backward to make their investment choices.
- Behavioral health continues to be a growing subspecialty; in part due to a decrease in the stigma surrounding mental health care and treatment, as well as an increase in access to care created by COVID-19 and the resulting expansion of telehealth services. This growth is predicted to continue as new legislation makes its way through Congress.
- Artificial intelligence (AI) is predicted to continue impacting all sectors of healthcare, with some of its strongest impact thus far seen in healthcare services and healthcare IT. Not only will AI increase the efficiency and quality of care provided to patients, but it will also impact revenue cycle management because it will reveal efficiencies, allowing companies to capitalize on them and improve existing processes for day-to-day operations. Likewise, AI will also help with the constraints placed on labor in the healthcare field and ultimately change how staffing is approached.
- Looking ahead to the rest of 2023, the panelists predicted that deal activity will continue to trend upward. PE firms will need to be creative in finding ways to navigate this rise in deal activity. If they focus on investing in strong companies that are improving health outcomes and access to care, exit paths will naturally reveal themselves.

HPE Miami 2023 | Washington Insights: Expected Federal Health Policy and Reimbursement Changes in 2023
ARTICLE
HPE Miami 2023 | Washington Insights: Expected Federal Health Policy and Reimbursement Changes in 2023
March 8-9, 2023
Read time: 3 min
During this session, Partner Eric Zimmerman moderated a panel that discussed anticipated areas of health policy development in 2023 in light of a new Republican-controlled Congress that has signaled its intent to increase oversight of the Biden administration.
Session panelists included:
- Debra Curtis, Vice President, McDermott+Consulting
- Brian Fortune, Senior Managing Director, Farragut Square Group
- Darren Patz, Esq., Immediate Past SVP & Chief Government Affairs Officer, Pediatrix Medical Group
Key takeaways included:
- Opposing political parties sharing power in the federal government does not necessarily create a deadlock. Generally speaking, Congress members are interested in advancing and passing legislation, so noncontroversial items should continue to move through Congress with ease despite requiring cooperation between Republicans and Democrats. Additionally, some bills must pass during each legislative session and pertinent social issues, such as crime, motivate legislative progress.
- In terms of presidential politics in 2023, expect the Biden administration to continue to advance healthcare legislation and policy in an ongoing contrast to the Trump administration. Given that any proposed bills would need to advance through a Republican-controlled Congress to become law, the Biden administration is likely to address controversial areas of healthcare policy via executive or administrative action. Legal challenges will continue to test the limits of what may be achieved by a presidential administration through executive action.
- Skepticism of private equity investment in the healthcare sector is likely to continue in 2023, both at the federal and state level. Several state legislatures, such as those in New York and Washington, have recently proposed legislation that would create significant regulatory hurdles for private equity transactions in the healthcare space. Additionally, several states, as well as the Federal Trade Commission, have demonstrated an increased interest in the enforceability of non-compete covenants that are standard in many healthcare transactions. Notably, the skepticism of private equity investment and efforts to regulate the industry are not limited to red or blue states but rather span across the political spectrum.
- To combat negative press directed toward private equity involvement in the healthcare sector, private equity firms should consider taking a more active role in creating a positive image in the eyes of the public. Many positive aspects of private equity investment in healthcare receive little-to-no attention in the press, such as creating greater access to healthcare in rural or underserved areas, lowering the cost of healthcare by causing a shift toward ambulatory care and contributing to innovation and efficiency in the industry.

HPE Miami 2023 | Strategies for Closing Healthcare Deals in Current Market Conditions
ARTICLE
HPE Miami 2023 | Strategies for Closing Healthcare Deals in Current Market Conditions
March 8-9, 2023
Read time: 3 min
During this session, Kristian Werling, McDermott partner and co-head of the Firm’s Private Equity Practice Group, moderated a panel that discussed the creative strategies private equity firms can employ to successfully close transactions in light of recent events that caused market instability.
Session panelists included:
- Michael Balmuth, Managing Partner, SV Health Investors
- Christian Chauvet, Partner, Lee Equity Partners, LLC
- Hank Mannix, Investment Partner, Kelso & Company
- Steve Tole, Managing Director, Head of Healthcare, William Blair
- Carl Zimmerman, Partner, Amulet Capital Partners, LP
Key takeaways included:
- The dynamics in physician practice transactions have changed over the past year because of challenging market conditions. While there has been a general decrease in the volume of transactions closing, there have also been new opportunities for private equity funds to work with successful practices that are feeling the negative impact of current market conditions.
- Minority deals have become increasingly challenging in the current market, due in part to the overvaluation of acquisitions that may have the effect of pricing smaller funds out of the market. However, many creative strategies can be implemented to close minority deals. For example, private equity funds might consider placing experienced executives in board seats in connection with acquisitions, which may help fuel growth in innovating areas. Additionally, putting in an early effort to form strong relationships with the owners of potential targets may help with pushing deals across the finish line.
- Exit strategies in the current economy vary depending on the size of the market. Most activity has recently been occurring in the under-$50 million market, where direct lenders are becoming increasingly aggressive. In larger markets, there has been a recent shift toward more refinancing opportunities as opposed to true exits, although some funds have turned to multi-lender solutions. Direct lenders sometimes collaborate in larger markets. As 2023 progresses, activity will likely increase in larger markets as market conditions improve.
- Private equity funds have been considering and utilizing several strategies to retain portfolio companies in the current market. One common tool being implemented is the use of continuation funds, which may mitigate the need to sell off portfolio companies during difficult market conditions. Additionally, many private equity funds are considering co-investment opportunities with other funds, which may help to spread out risks and fund transactions.

HPE Miami 2023 | Getting Tactical: What Healthcare Investment Bankers Think
ARTICLE
HPE Miami 2023 | Getting Tactical: What Healthcare Investment Bankers Think
March 8-9, 2023
Read time: 3 min
During this session, Partner David Ivill moderated a panel featuring investment bankers at leading financial institutions that discussed the big economic themes they predict for the year ahead, particularly as they impact healthcare investing, a sector that has historically outpaced other industries during past slumps.
Session panelists included:
- Phil Colaco, CEO, Deloitte Corporate Finance LLC
- Mark Francis, Managing Director and Global Head of Healthcare, Houlihan Lokey
- Michael Gerardi, Global Co-Head of Healthcare Investment Banking , Jefferies & Company
- Matthew McAskin, Senior Managing Director, Evercore
- Emily Wildes, Managing Director, Lincoln International
Key takeaways included:
- Economic headwinds such as inflation, interest rate hikes, recession fears and geopolitical uncertainty have changed the market. Many private equity groups have become less active and more disciplined with a heightened focus on due diligence. Strategic buyers have become bifurcated, with large retail pharmaceutical companies, retail care companies and similar strategic buyers continuing to embrace the risky environment while others pull back.
- Certain provider services, such as physical therapy, hospitals and large corporate and strategic businesses, have suffered disproportionately, largely because of upward wage pressure, burnout and turnover. Conversely, there are plenty of opportunities in the cash pay elements of healthcare, such as fertility services, aesthetics and veterinary, due in part to payor rates trailing inflation. Other areas of opportunity include home health and ambulatory health.
- Great businesses continue to sell at a premium price despite the economic headwinds. However, there are fewer of those businesses now compared to a year ago. The current market largely consists of buyers and sellers who need to do deals (because of economic conditions or otherwise) and best-in-class acquisition targets.
- Other factors that will affect valuations in 2023 include financing, fundamentals and creativity. Uncertainty around interest rates makes it difficult for buyers to appropriately price deals. Uncertainty around margins, wage inflation and recessionary risk separates the best-in-class management teams from the rest. Structured notes and other creative forms of financing are becoming more common ways to bridge valuation gaps.
- Price, speed and certainty are fundamental to making prospective buyers stand out, followed by experience in the sector and relationships. However, this is complicated by heightened risks in the diligence and regulatory approval processes and a general sentiment of risk aversion.
- Distressed transactions are already increasing in frequency and will continue to do so. Precursors for distress, including divestitures, will become more common, particularly on the hospital side. Private equity can often solve for distressed businesses in attractive sectors because of a weak balance sheet or poor management.